SOLICITATION NOTICE
B -- characterizing the neurological disease genes using Drosophila
- Notice Date
- 5/22/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2014-132-DLM
- Archive Date
- 6/11/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, 1600 NW 10th Ave, RMSB 6069, Miami, FL 33136 to continue providing research on characterizing the neurological disease genes using Drosophila by Rescue analysis for NHGRI Undiagnosed Disease Program (UDP). This is a Follow-On Requirement. BACKGROUND: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI) mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. To that end NHGRI supports the development of resources and technology that will accelerate genome research and its application to human health. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. NHGRI Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, MD. Many medical specialties from other NIH research centers and institutes contribute the expertise needed to conduct the program, including endocrinology, immunology, oncology, dermatology, dentistry, cardiology and genetics, among the dozens of participating senior attending physicians. A longstanding medical condition that eludes diagnosis by a referring physician can be considered undiagnosed and may be of interest to this clinical research program. Based on the previous contract results from University of Miami, Miller School of Medicine, Department of Molecular and Cellular Pharmacology: each of the genes has been functionally analyzed in Drosophila for the role of the encoded proteins in neurodevelopment and neurodegeneration by obtaining transgenic RNAi mutant alleles for the Drosophila homologue of the candidate genes, establishing nervous system specific loss-of-function fly strains, and detailed analysis of the gross, systemic, neurological and behavior phenotypes including motor coordination. Due to these amazing results, the NHGRI Undiagnosed Disease Program deemed that the screening process was successful and that UDP requires rescue analysis to be performed for 5 genes of interest and mechanistic analysis of 4 genes associated in UDP patient disorders. Period of Performance: July 2014 through January 2016 PROCUREMENT: 1. Rescue analysis for 5 genes and mechanistic analysis for 4 genes/diseases; a. Rescue analysis of candidate genes with known neurological phenotypes identified in the UDP laboratory; and b. Mechanistic analyses of candidate genetic mutations identified in UDP on the following four genes: SMS, Ube2v2, SPRK, and SLC13A5. JUSTIFICATION: Miami University School of Medicine, Department of Molecular and Cellular Pharmacology laboratory has established a robust methodology for characterizing the neurological disease genes using Drosophila. It also supports the ongoing collaborative research expertise needed by the National Human Genome Research Institute (NHGRI), Undiagnosed Disease Program (UDP). Miami University School of Medicine, Department of Molecular and Cellular Pharmacology is uniquely qualified and possesses the knowledge, history and expertise for this contract. Miami has invested several years developing the technology and expertise required for these analyses. CONTRACTOR REQUIREMENTS: • The Contractor shall supply electronic copies of all reports appropriate for deposition in the UDP process management system and for other collaborations as well as participate in publication of results. • Rescue Analysis on 5 genes o Establish transgenic lines carrying human genes, wild type and mutant alleles consisting of 2 transgenic lines per allele, 4 to 6 lines per gene. o Recombine transgenic chromosome with RNAi chromosome to establish double transgenic lines (three-generation genetic crosses to establish 4 to 6 lines per gene; Genotype: (1) UAS-WT;UAS-RNAi, (2/3) UAS-mut1/2;UAS-RNAi, (4) UAS-ctrl;UAS-RNAi). o Establish global loss-of-function fly strains (10 crosses will be set up per allele, 50 to 70 crosses per gene). o Analyze the gross and systemic phenotypes including survival and lifespan (100 flies will be analyzed per allele, 500 to 700 flies per gene). o Establish nervous system specific loss-of-function fly strains (10 crosses will be set up per allele, 50 to 70 crosses per gene). o Analyze neurological and behavior phenotypes including motor coordination (100 flies will be analyzed per allele, 500 to 700 flies per gene). • Mechanistic analysis of 4 candidate genes that have been found in UDP patients in the following 4 genes: SMS, Ube2v2, SRPK, SLC13A5 • Functionally characterize the loss of function phenotypes with RNAi and mutant alleles. • Cellular analysis of gene expression and protein function. • Detailed rescue analyses, phenotypic comparison with human data, and manuscript preparation. REGULATORY AUTHORITY: This acquisition is conducted under the authority of 41 U.S.C. 253(c) as set forth in FAR Part 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) and the Small Business Size Standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-73 (April 29, 2014). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by May 27, 2014 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-132-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2014-132-DLM/listing.html)
- Place of Performance
- Address: NIH, Rockville, Maryland, United States
- Record
- SN03374522-W 20140524/140522235744-0e29054c9c7ab109d7d3b563b5f076ff (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |